Clinical & Regulatory Updates Topic Center

News

FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer

03/11/2026

Stephanie Holland

Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.

Based on results from the OSPREY...

03/11/2026

Radiopharmaceutical Education Institute

Videos

Radium-223 Plus Enzalutamide Improves Survival in Bone-Predominant Metastatic Castration-Resistant Prostate Cancer

03/05/2026

Bertrand Tombal, MD, PhD

Bertrand Tombal, MD, PhD, discusses final overall survival results from the EORTC 1333/PEACE-3 trial evaluating enzalutamide with or without radium-223 in patients with metastatic castration-resistant prostate cancer and bone metastases.

Bertrand Tombal, MD, PhD,...

03/05/2026

Radiopharmaceutical Education Institute

Videos

Clonal Hematopoiesis Expansion Following 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer

02/26/2026

Alexander Wyatt, PhD

Alexander Wyatt, PhD, discusses results from a post hoc correlative analysis of the phase 2 TheraP trial comparing 177Lu-PSMA-617 with standard cabazitaxel chemotherapy in patients with metastatic castration-resistant prostate cancer.

Alexander Wyatt, PhD, discusses...

02/26/2026

Radiopharmaceutical Education Institute

Videos

Addition of 177Lu-PSMA-617 for Patients With Metastatic Hormone-Sensitive Prostate Cancer

10/30/2025

Scott Tagawa, MD

Scott Tagawa, MD, Weill Cornell Medicine, discusses results from the phase 3 PSMAddition trial evaluating the addition of 177Lu-PSMA-617 to androgen deprivation therapy and androgen receptor pathway inhibitor therapy for patients with...

Scott Tagawa, MD, Weill Cornell...

10/30/2025

Radiopharmaceutical Education Institute

News

177Lu-PSMA-617 Added to Standard of Care Improves Radiographic PFS in Metastatic Hormone-Sensitive Prostate Cancer

10/19/2025

Stephanie Holland

Adding 177Lu-PSMA-617 to standard androgen deprivation therapy plus an androgen receptor pathway inhibitor significantly improved radiographic PFS in metastatic hormone-sensitive prostate cancer, according to a second interim analysis from...

Adding 177Lu-PSMA-617 to...

10/19/2025

Radiopharmaceutical Education Institute

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...

Based on results from the...

03/28/2025

Radiopharmaceutical Education Institute

Conference Coverage

[177Lu]Lu-PSMA-617 Plus Enzalutamide Boosts Survival, Quality of Life for Poor-Risk Metastatic Castration-Resistant Prostate Cancer

02/13/2025

Allison Casey

The addition of [177Lu]Lu-PSMA-617 to enzalutamide improved the overall survival and several quality-of-life measures among patients with poor-risk, metastatic castration-resistant prostate cancer.

The addition of...

02/13/2025

Oncology

Philip Kuo, MD, PhD, University of Arizona Cancer Center

Videos

Association Between Baseline PSMA Expression and Response to 177Lu-PSMA-617 Among Patients with Metastatic Castration-Resistant Prostate Cancer

11/10/2023

Philip Kuo, MD, PhD

Philip Kuo, MD, PhD, shares results from a sub-study of the phase 3 VISION trial, investigating the association between baseline PSMA expression and response to 177Lu-PSMA-617 therapy among patients with metastatic castration-resistant...

Philip Kuo, MD, PhD, shares...

11/10/2023

Oncology

News

Addition of 177Lu-PSMA-617 to Enzalutamide Improves PSA Outcomes Among Patients With Metastatic Castration-Resistant Prostate Cancer

11/06/2023

Allison Casey

A phase 2 study found that adding adaptive-dosed 177Lu-PSMA-617to enzalutamide improved several PSA-based outcomes among patients with metastatic castration-resistant prostate cancer.

A phase 2 study found that...

11/06/2023

Oncology

Videos

¹⁷⁷Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

10/25/2023

Oliver Sartor, MD

At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.

At the 2023 ESMO Congress,...

10/25/2023

Oncology

Advancing Oncology Through Radiopharmaceutical Innovation

The Radiopharmaceutical Education Institute (RPEI) is dedicated to advancing the science and clinical integration of radiopharmaceutical therapies in oncology. Through accessible, expert-driven education and multidisciplinary dialogue, we aim to equip clinicians with the insight and evidence needed to inform treatment decisions and shape the future of radiopharmaceutical innovation in cancer care.

Clinical & Regulatory Updates Topic Center

Advancing Oncology Through Radiopharmaceutical Innovation

HMP Global Products

Events